RGL-305

RGL-305 is an investigational cell therapy being developed for the treatment of lymphoma. In an open, dose-escalation clinical trial, RGL-305 is administered to patients with lymphoma who have achieved complete response (CR) or partial response (PR) but remain minimal residual disease (MRD) positive after standard therapy. This therapy involves the reinfusion of RGL-305 cells, and the study aims to evaluate its safety, cytodynamics, and initial efficacy. The trial uses a "3+3" dose escalation design and involves cell transfusions every two weeks for up to five cycles or until disease recurrence, progression, or unacceptable toxicity. The specific cellular modality and mechanism of action are not stated in available sources, but it is described as a cell therapy administered as a transfusion[1][4][8].